0001104659-24-031575.txt : 20240306
0001104659-24-031575.hdr.sgml : 20240306
20240306181722
ACCESSION NUMBER: 0001104659-24-031575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BILINSKY IGOR
CENTRAL INDEX KEY: 0001594604
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 24727474
MAIL ADDRESS:
STREET 1: C/O VICAL INCORPORATED
STREET 2: 10390 PACIFIC CENTER COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm248073-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-04
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001594604
BILINSKY IGOR
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
CA
94070
0
1
0
0
Chief Operating Officer
0
Common Stock
2024-03-04
4
M
0
14061
0
A
43928
D
Common Stock
2024-03-04
4
F
0
7287
16.96
D
36641
D
Restricted Stock Units
2024-03-04
4
M
0
14061
0.00
D
Common stock
14061
28129
D
Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
Represents common stock remaining after deducting the common stock withheld for taxes.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The remaining RSUs will vest in equal quarterly installments.
Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
/s/ Igor Bilinsky
2024-03-06